Gland Pharma has announced the appointment of Srinivas Sadu, the current Managing Director (MD) and CEO, as the Executive Chairman and CEO of the company, effective from June 10, 2024. Srinivas Sadu, a seasoned professional with over two decades of experience, has been a pivotal part of Gland’s journey.Mr. Sadu assumed the role of MD and CEO on April 25, 2019, and has played a significant role in driving the company’s growth and success. His association with Gland Pharma dates back to 2000, and he has steadily progressed through various roles within the organization, culminating in his appointment as chief operating officer in 2011.
Under Mr. Sadu’s leadership, Gland Pharma has witnessed substantial growth and has secured significant achievements. The company’s consolidated profit after tax (PAT) surged over two-fold to Rs 192 crore for the March quarter, compared to Rs 79 crore reported in the year-ago period. Additionally, revenue from operations rose to Rs 1,537 crore in Q4 FY24 as against Rs 785 crore in the corresponding period last year.Shares of Gland Pharma Ltd ended positively at ₹1,853.40, up by ₹16.65, or 0.91% on the BSE.
Gland Pharma is a Hyderabad-based pharmaceutical company known for its innovative products and commitment to quality. This appointment further solidifies the company’s leadership team and its commitment to driving growth and delivering value to its stakeholders.
